Anticardiolipin Antibodies Block the Inhibition by β₂-Glycoprotein I of the Factor Xa Generating Activity of Platelets

Summary

Antiphospholipid antibodies, defined either by lupus anticoagulant (LA) activity or positive anticardiolipin immunoabsorbent assay (ACA) are associated with a predisposition to thromboses, recurrent fetal loss or thrombocytopenia. The mechanisms for these predispositions remain undefined. We have enriched immunoglobulin fractions from two patient plasmas to obtain antibodies with LA activity but no ACA, or conversely, with ACA positivity but no LA, in order to investigate in vitro characteristics which might explain a thrombotic propensity. β₂-glycoprotein I (β₂-GPI), the plasma cofactor required for ACA binding to negatively charged phospholipid, has previously been shown to inhibit prothrombinase generation in the presence of activated platelets (8). We now report that β₂-GPI, at physiological concentrations, inhibits the generation of factor Xa in the presence of activated gel-filtered platelets. Further, ACA interferes with this inhibition, resulting in protracted, unopposed factor Xa generation. This interference with β₂-GPI, a natural anticoagulant component of plasma, is potentially prothrombotic. LA immunoglobulins behave differently and inhibit factor Xa generation in a manner similar to β₂-GPI. These findings provide the basis for a previously unsuspected mechanism for thrombosis in patients with aPL.

• References

• 1 McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280
• 2 Shi W, Chong BH, Chesterman CN. β₂-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: difference with lupus anticoagulants. Blood 1993; 81: 1255-1262
• 3 McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989; 73: 506-513
• 4 Exner T, Sahman N, Trudinger B. Separation of anticardiolipin antibodies from lupus anticoagulant on a phospholipid-coated polystyrene column. Biochem Biophys Res Commun 1988; 155: 1001-1007
• 5 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
• 6 Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, Van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
• 7 Schousboe I. β₂-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-1091
• 8 Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RFA. Prothrombinase activity of human platelets is inhibited by β₂-glycoprotein I. Biochem Biophys Acta 1986; 884: 142-149
• 9 Nimpf J, Wurm H, Kostner GM. β₂-glycoprotein I (apo H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 109-114
• 10 Hughes GRV. The anticardiolipin syndrome. Clin Exp Rheumatol 1985; 3: 285-286
• 11 Exner T, Richard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns. Br J Haematol 1978; 40: 143-151
• 12 McNeil HP, Krilis SA, Chesterman CN. Purification of antiphospholipid antibodies using a new affinity method. Thromb Res 1988; 52: 641-648
• 13 Rosing J, van Rijn JLML, Bevers EM, van Dieijen G, Comfurius P, Zwaal RFA. The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65: 319-332
• 14 Sims PJ, Wiedmer T, Esmon CT, Weiss JH, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-17057
• 15 Propert DN. The relation of sex smoking status, birth rank and parental age to β₂-glycoprotein I levels and phenotypes in a sample of Australian Caucasian adults. Hum Genet 1978; 43: 281-288
• 16 Bancsi LFJMM, van der LindenIK, Bertina RM. β₂-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemostas 1992; 67: 649-653
• 17 Miletich J, Sherman L, Broze Jr G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-996
• 18 Huang C-H. Studies on phosphatidylcholine vesicles. Formation and physical characteristics. Biochemistry 1969; 8: 344-352
• 19 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemostas 1991; 66: 629-632
• 20 Oosting JD, Derksen RHWM, Entijes HTI, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of β₂-glycoprotein I. Thromb Haemostas 1992; 67: 499-502
• 21 Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β₂-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemostas 1992; 68: 297-300
• 22 Brandt JT. Assays for phospholipid-dependent formation of thrombin and Xa: a potential method for quantifying lupus anticoagulant activity. Thromb Haemostas 1991; 66: 453-458